Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

164.41USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$164.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
993,351
52-wk High
$181.76
52-wk Low
$129.50

Select another date:

Fri, Dec 2 2016

Becton Dickinson wins reversal of $340 million syringe award

A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co to pay rival Retractable Technologies Inc $340 million in damages over its marketing of safety syringes.

BRIEF-Becton Dickinson board increases dividend

* Declared a quarterly dividend of $0.73 per common share, an increase of 10.6 percent from previous quarter Source text for Eikon: Further company coverage:

BRIEF-Becton, Dickinson and Co announces tender offers for outstanding debt securities

* Becton, Dickinson and Company announces tender offers for outstanding debt securities

BRIEF-Becton Dickinson launches syringe for use with Humulin R U-500 insulin

* BD launches first syringe designed for use with Humulin R U-500 insulin Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-BD reports results for Q4 provides full-year fiscal 2017 guidance

* Becton Dickinson and Co - expects full fiscal year 2017 revenues to decrease 3.0 to 3.5 percent

BRIEF-BD says Max Vaginal Panel receives FDA market authorization for test

* Bd max vaginal panel receives fda market authorization to detect most common causes of vaginal infections Source text for Eikon: Further company coverage:

BRIEF-Becton Dickinson expects a material tax loss on Apax JV deal

* Becton Dickinson and Co expects to record a material tax loss on Apax JV deal at time of closing Source text for Eikon: Further company coverage: ;))

BRIEF-Becton Dickinson invests $100 mln in Nebraska plant to expand insulin syringe manufacturing

* BD invests $100 million in Nebraska plant to expand insulin syringe manufacturing

BRIEF-BD submits pre-market approval application to FDA for BD Onclarity HPV test

* Says intends to ultimately seek approval using HPV genotyping beyond 16, 18 and 45 Source text for Eikon: Further company coverage:

BRIEF-Becton Dickinson names Andrew Eckert to board of directors

* Names Andrew Eckert to board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Select another date: